Heart rate and use of beta-blockers in stable outpatients with coronary artery disease.
<h4>Background</h4>Heart rate (HR) is an emerging risk factor in coronary artery disease (CAD). However, there is little contemporary data regarding HR and the use of HR-lowering medications, particularly beta-blockers, among patients with stable CAD in routine clinical practice. The goa...
Guardado en:
Autores principales: | Ph Gabriel Steg, Roberto Ferrari, Ian Ford, Nicola Greenlaw, Jean-Claude Tardif, Michal Tendera, Hélène Abergel, Kim M Fox, CLARIFY Investigators |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2158c5199d7b4819ab00a35f107c5f4b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Transdermal Patches for Delivery of Beta-Blockers
por: Rohaľová S., et al.
Publicado: (2021) -
Beta-blockers provide a differential survival benefit in patients with coronary artery disease undergoing contemporary post-percutaneous coronary intervention management
por: Pil Hyung Lee, et al.
Publicado: (2020) -
Poor tolerance of beta-blockers by elderly patients with heart failure
por: Satoshi Yanagisawa, et al.
Publicado: (2010) -
Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis.
por: Feng Liu, et al.
Publicado: (2014) -
Hypertension and COVID-19: Potential use of beta-blockers and a call for randomized evidence
por: Mochamad Yusuf Alsagaff, et al.
Publicado: (2021)